Assessment of immunity to polio among Rohingya children in Cox's Bazar, Bangladesh, 2018: A cross-sectional survey.
Adolescent
Bangladesh
/ epidemiology
Child
Child, Preschool
Cross-Sectional Studies
Female
Humans
Infant
Male
Myanmar
/ ethnology
Poliomyelitis
/ epidemiology
Poliovirus Vaccine, Oral
/ administration & dosage
Prevalence
Refugees
/ statistics & numerical data
Seroepidemiologic Studies
Vaccination
/ statistics & numerical data
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
27
09
2019
accepted:
27
02
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
25
6
2020
Statut:
epublish
Résumé
We performed a cross-sectional survey in April-May 2018 among Rohingya in Cox's Bazar, Bangladesh, to assess polio immunity and inform vaccination strategies. Rohingya children aged 1-6 years (younger group) and 7-14 years (older group) were selected using multi-stage cluster sampling in makeshift settlements and simple random sampling in Nayapara registered camp. Surveyors asked parents/caregivers if the child received any oral poliovirus vaccine (OPV) in Myanmar and, for younger children, if the child received vaccine in any of the 5 campaigns delivering bivalent OPV (serotypes 1 and 3) conducted during September 2017-April 2018 in Cox's Bazar. Dried blood spot (DBS) specimens were tested for neutralizing antibodies to poliovirus types 1, 2, and 3 in 580 younger and 297 older children. Titers ≥ 1:8 were considered protective. Among 632 children (335 aged 1-6 years, 297 aged 7-14 years) enrolled in the study in makeshift settlements, 51% were male and 89% had arrived after August 9, 2017. Among 245 children (all aged 1-6 years) enrolled in the study in Nayapara, 54% were male and 10% had arrived after August 9, 2017. Among younger children, 74% in makeshift settlements and 92% in Nayapara received >3 bivalent OPV doses in campaigns. Type 1 seroprevalence was 85% (95% CI 80%-89%) among younger children and 91% (95% CI 86%-95%) among older children in makeshift settlements, and 92% (88%-95%) among younger children in Nayapara. Type 2 seroprevalence was lower among younger children than older children in makeshift settlements (74% [95% CI 68%-79%] versus 97% [95% CI 94%-99%], p < 0.001), and was 69% (95% CI 63%-74%) among younger children in Nayapara. Type 3 seroprevalence was below 75% for both age groups and areas. The limitations of this study are unknown routine immunization history and poor retention of vaccination cards. Younger Rohingya children had immunity gaps to all 3 polio serotypes and should be targeted by future campaigns and catch-up routine immunization. DBS collection can enhance the reliability of assessments of outbreak risk and vaccination strategy impact in emergency settings.
Sections du résumé
BACKGROUND
We performed a cross-sectional survey in April-May 2018 among Rohingya in Cox's Bazar, Bangladesh, to assess polio immunity and inform vaccination strategies.
METHODS AND FINDINGS
Rohingya children aged 1-6 years (younger group) and 7-14 years (older group) were selected using multi-stage cluster sampling in makeshift settlements and simple random sampling in Nayapara registered camp. Surveyors asked parents/caregivers if the child received any oral poliovirus vaccine (OPV) in Myanmar and, for younger children, if the child received vaccine in any of the 5 campaigns delivering bivalent OPV (serotypes 1 and 3) conducted during September 2017-April 2018 in Cox's Bazar. Dried blood spot (DBS) specimens were tested for neutralizing antibodies to poliovirus types 1, 2, and 3 in 580 younger and 297 older children. Titers ≥ 1:8 were considered protective. Among 632 children (335 aged 1-6 years, 297 aged 7-14 years) enrolled in the study in makeshift settlements, 51% were male and 89% had arrived after August 9, 2017. Among 245 children (all aged 1-6 years) enrolled in the study in Nayapara, 54% were male and 10% had arrived after August 9, 2017. Among younger children, 74% in makeshift settlements and 92% in Nayapara received >3 bivalent OPV doses in campaigns. Type 1 seroprevalence was 85% (95% CI 80%-89%) among younger children and 91% (95% CI 86%-95%) among older children in makeshift settlements, and 92% (88%-95%) among younger children in Nayapara. Type 2 seroprevalence was lower among younger children than older children in makeshift settlements (74% [95% CI 68%-79%] versus 97% [95% CI 94%-99%], p < 0.001), and was 69% (95% CI 63%-74%) among younger children in Nayapara. Type 3 seroprevalence was below 75% for both age groups and areas. The limitations of this study are unknown routine immunization history and poor retention of vaccination cards.
CONCLUSIONS
Younger Rohingya children had immunity gaps to all 3 polio serotypes and should be targeted by future campaigns and catch-up routine immunization. DBS collection can enhance the reliability of assessments of outbreak risk and vaccination strategy impact in emergency settings.
Identifiants
pubmed: 32231366
doi: 10.1371/journal.pmed.1003070
pii: PMEDICINE-D-19-03533
pmc: PMC7108688
doi:
Substances chimiques
Poliovirus Vaccine, Oral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003070Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: JMA is a Health Specialist at UNICEF Bangladesh. MH is a Health Specialist at UNICEF Bangladesh.
Références
MMWR Morb Mortal Wkly Rep. 2016 Aug 05;65(30):763-9
pubmed: 27491079
MMWR Morb Mortal Wkly Rep. 2015 Aug 28;64(33):913-7
pubmed: 26313474
Lancet Infect Dis. 2012 Feb;12(2):128-35
pubmed: 22071249
Bull World Health Organ. 1995;73(6):769-77
pubmed: 8907770
Lancet Infect Dis. 2015 Aug;15(8):898-904
pubmed: 26093980
Vaccine. 2014 Sep 3;32(39):4893-900
pubmed: 25045821
Emerg Infect Dis. 2018 Jul;24(7):1188-1194
pubmed: 29912680
Vaccine. 2013 Apr 8;31(15):1987-93
pubmed: 23429005
Vaccine. 2017 Oct 9;35(42):5693-5699
pubmed: 28882442
Wkly Epidemiol Rec. ;92(22):301-20
pubmed: 28580777
J Infect Dis. 1997 Feb;175 Suppl 1:S258-63
pubmed: 9203726
Vaccine. 2014 Mar 10;32(12):1414-20
pubmed: 24041545
JAMA. 2018 Apr 10;319(14):1505-1506
pubmed: 29634821
Lancet. 2010 Nov 13;376(9753):1682-8
pubmed: 20980048
Curr Opin Virol. 2013 Jun;3(3):309-15
pubmed: 23759252
MMWR Morb Mortal Wkly Rep. 2016 Sep 09;65(35):934-8
pubmed: 27606675
Methods Mol Biol. 2016;1387:145-76
pubmed: 26983734
Lancet. 2007 Apr 21;369(9570):1356-1362
pubmed: 17448821
Vaccine. 2013 Oct 1;31(42):4911-6
pubmed: 23891502
Wkly Epidemiol Rec. 2016 Mar 25;91(12):145-68
pubmed: 27039410
MMWR Morb Mortal Wkly Rep. 2007 Sep 28;56(38):996-1001
pubmed: 17898693
Vaccine. 2016 May 11;34(22):2519-26
pubmed: 27085172
MMWR Morb Mortal Wkly Rep. 2018 May 11;67(18):533-535
pubmed: 29746454
J Infect Dis. 2014 Nov 1;210 Suppl 1:S225-33
pubmed: 25316839